It was a roller coaster of a month for the biotech.
News & Analysis: Alexion Pharmaceuticals
Why American Outdoor Brands, Innovative Industrial Properties, and Alexion Pharmaceuticals Slumped Today
Find out what caused these very different companies all to lose ground.
Rumors that Amgen plans to buy Alexion might not become reality. But a deal would make a lot of sense.
Two great biotechs focused on rare diseases. But one of them gets the nod as the better pick.
The biotech's rare-disease drugs continued to generate strong sales growth.
ALXN earnings call for the period ending June 30, 2019.
Great growth prospects and relatively modest risk levels make these biotech stocks really attractive.
Seven simple steps to improving your chances of success in this part of the market.
It can be tough to pick winners in the world of pharmaceutical development, but Alexion, Regeneron, and Ionis offer investors good chances of strong returns.
Not all stocks are expensive. These drug stocks look like bargains.